<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-36712" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Splanchnic Venous Thrombosis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Akhondi</surname>
            <given-names>Hossein</given-names>
          </name>
          <aff>University of Nevada</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ganjali</surname>
            <given-names>Shirin</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nagalli</surname>
            <given-names>Shivaraj</given-names>
          </name>
          <aff>Yuma Regional Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hossein Akhondi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shirin Ganjali declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shivaraj Nagalli declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>4</day>
          <month>7</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-36712.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Splanchnic venous thrombosis (SVT) is characterized by the formation of blood clots within the veins of the splanchnic circulation, including the splenic, mesenteric, portal, and hepatic veins. The portal and mesenteric veins are most commonly affected, while hepatic vein thrombosis, known as Budd-Chiari syndrome, is less frequent. SVT can present with a wide range of symptoms depending on the location of the thrombosis, often leading to abdominal pain, gastrointestinal disturbances, and potential complications such as bowel ischemia. Early diagnosis through imaging, like Doppler ultrasound or computed tomography scans, and prompt anticoagulation therapy are crucial for effective management.</p>
        <p>Participants in this course gain an understanding of the pathophysiology, diagnosis, and treatment of splanchnic venous thrombosis. The course emphasizes the importance of using advanced diagnostic tools, recognizing the varied presentations of the condition, and implementing evidence-based management strategies, including anticoagulation therapy. Collaboration among an interprofessional team, including radiologists, gastroenterologists, hematologists, and primary care clinicians, enhances patient outcomes by facilitating timely diagnosis, optimizing treatment decisions, and ensuring comprehensive patient care</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the early signs and symptoms of splanchnic venous thrombosis in patients presenting with unexplained abdominal pain.</p></list-item><list-item><p>Differentiate between splanchnic venous thrombosis and other causes of abdominal pain using clinical and imaging criteria.</p></list-item><list-item><p>Implement evidence-based anticoagulation therapy for the management of symptomatic splanchnic venous thrombosis.</p></list-item><list-item><p>Communicate&#x000a0;the interprofessional team strategies for improving care coordination and communication in splanchnic venous thrombosis to improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=36712&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=36712">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-36712.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Abdominal veins bring blood lacking oxygen from the abdomen to the inferior vena cava, draining to the right atrium. Abdominal organs have&#x000a0;2 venous systems: the systemic one, which drains directly to the inferior vena cava, and the portal one, which drains to the hepatic portal vein and then to the inferior vena cava through the liver. The systemic venous system includes common iliac, lumbar, renal, right testicular/ovarian, right suprarenal, inferior phrenic, and hepatic veins. The portal venous system includes right and left gastric, cystic, para-umbilical, splenic, inferior mesenteric (via a splenic vein), and superior mesenteric vein. The splenic and superior mesenteric merge to form the portal vein. Blood clotting in these venous systems can lead to splanchnic venous thrombosis; this includes thrombosis in the splenic, mesenteric, portal, or hepatic veins (eg, Budd-Chiari syndrome). The most common site of venous thrombosis is a portal and mesenteric vein, with the least common being the hepatic vein.<xref ref-type="bibr" rid="article-36712.r1">[1]</xref> Splanchnic venous thrombosis can lead to different symptoms depending on the site of the thrombosis.</p>
      </sec>
      <sec id="article-36712.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Left-sided portal hypertension results from complete obstruction of the splenic vein; this does not occur in all cases due to anatomic variants as many patients are asymptomatic. Significant splenomegaly may be detected on imaging. The patient may present with typical signs of portal hypertension, including gastroesophageal varices, ascites, and splenomegaly, which cannot be attributed to hepatic disease. Some of the complications of splanchnic venous thrombosis include gastrointestinal bleeding, esophageal or gastric varices, intestinal ischemia, anemia, thrombocytopenia, and infection.</p>
      </sec>
      <sec id="article-36712.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The incidence and prevalence of splanchnic vein thrombosis are on the rise. This pattern is partially attributed to the widespread use of computed tomography that picks up this disease as a confirmation of clinical&#x000a0;judgment&#x000a0;or sometimes incidentally. Results from one study in Sweden noted an increase from 2 to 2.7 cases per 100,000 between the 1970s and 2000s.<xref ref-type="bibr" rid="article-36712.r2">[2]</xref>&#x000a0;The most common leading cause of portal vein thrombosis is liver cirrhosis. Among patients with cirrhosis, ultrasound has shown a prevalence of 5% to 24% for portal vein thrombosis. In contrast, the autopsy of patients who died of cirrhosis has reported a prevalence of 6% to 64%. The prevalence is unknown in individuals who are non-cirrhotic.<xref ref-type="bibr" rid="article-36712.r3">[3]</xref></p>
        <p>Chronic pancreatitis is the most common reason for splenic vein thrombosis. Splenic vein thrombosis was reported in 11% of the results from a study and 5% to 22% of patients with chronic pancreatitis in another study.<xref ref-type="bibr" rid="article-36712.r4">[4]</xref> Gastric variceal bleeding is the initial presentation in between 45% to 72% of patients with splenic vein thrombosis.&#x000a0;Some study results have shown that acute mesenteric venous thrombosis is the cause of acute mesenteric ischemia in 2% to 10% of the cases.<xref ref-type="bibr" rid="article-36712.r5">[5]</xref> Two reviews have reported that of all cases of mesenteric venous thrombosis, only 24% to 40% were chronic mesenteric venous thrombosis. Chronic mesenteric venous thrombosis is noted less than acute thrombosis because of lower incidence or a lack of symptoms. Hepatic venous thrombosis is more predominant in women in their 30s or 40s in non-Asian countries. One study in Italy produced results showing an incidence rate of 2.2 and 2.0 per million in women and men, respectively. In contrast, hepatic venous thrombosis is more common in men than in women in Asian countries.<xref ref-type="bibr" rid="article-36712.r6">[6]</xref> &#x000a0;</p>
      </sec>
      <sec id="article-36712.s5" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Sudden abdominal pain is the most common presentation of acute splanchnic venous thrombosis. Pain is absent in most cases of chronic venous thrombosis. Instead, these chronic cases present mostly with&#x000a0;upper gastrointestinal bleeding secondary to varices.<xref ref-type="bibr" rid="article-36712.r7">[7]</xref>&#x000a0;Specifically, patients with acute portal vein thrombosis usually present with severe abdominal pain and nausea in the absence of endoscopic findings. Chronic cases can have esophageal or gastric varices, which can lead to gastrointestinal bleeding. Splenomegaly, ascites, and palmar erythema are common in such cases. However, portal vein thrombosis can also be asymptomatic and can be discovered incidentally when a patient undergoes abdominal imaging for any other reason. Portal vein thrombosis can compress bile ducts and cause biliary symptoms due to cholangiopathy and present with fever, pruritus, jaundice, and right upper quadrant abdominal pain. Although portal vein thrombosis usually has regular liver function tests, hyperbilirubinemia and&#x000a0;increased alkaline phosphate levels can be present in cholangiopathy patients.<xref ref-type="bibr" rid="article-36712.r7">[7]</xref></p>
        <p>Splenic vein thrombosis presents in most cases with gastric varices. If there are gastric varices but no esophageal varices, or if gastric varices are more prominent than esophageal varices, then splenic vein thrombosis should be suspected.<xref ref-type="bibr" rid="article-36712.r8">[8]</xref> Patients with splenic vein thrombosis can be asymptomatic or can present with a variety of symptoms. These symptoms include abdominal pain, variceal bleeding, splenomegaly, and thrombocytopenia.</p>
        <p>Acute mesenteric venous thrombosis can lead to mesenteric ischemia and intestinal infarction, which presents with sudden periumbilical abdominal pain out of proportion to the clinical exam. Abdominal distention might be present on physical exam, and an occult blood test may be positive. Subacute mesenteric venous thrombosis can ensue when venous thrombosis is present, but there is also partial compensation through collateral vessels that allow for some circulation. Therefore, subacute thrombosis can last days to weeks before any symptom is present. In these patients, the most common presentation is nonspecific abdominal pain. Chronic mesenteric thrombosis is usually asymptomatic and found accidentally on abdominal imaging.<xref ref-type="bibr" rid="article-36712.r9">[9]</xref>&#x000a0;Acute hepatic venous thrombosis presents with fever, abdominal pain, and jaundice, with or without hepatic encephalopathy. In contrast, 15% to 20% of patients with subacute or chronic hepatic venous thrombosis are asymptomatic.<xref ref-type="bibr" rid="article-36712.r10">[10]</xref> In chronic cases, symptoms occur when the patient is cirrhotic. These symptoms include palmar erythema, spider angioma, ascites due to portal hypertension, and esophageal varices.&#x000a0;</p>
      </sec>
      <sec id="article-36712.s6" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>
<bold>Imaging</bold>
</p>
        <p>Computed tomography (CT) is the diagnostic method of choice in splanchnic vein thrombosis. In right upper quadrant abdominal pain cases, the first study to perform is typically a Doppler ultrasound, which is less costly and more comfortable than a CT scan or magnetic resonance imaging (MRI). In portal vein thrombosis, Doppler ultrasound shows hyperechoic material in the portal vein. Based on the thrombus caliber, there could be a decrease or even no flow to the portal vein. The mesenteric or splenic veins can also be enlarged since they merge to make the hepatic portal vein. If portal vein thrombosis is strongly suspected, it is best to omit the ultrasound and start with a CT scan or MRI of the abdomen (CT scan is preferred over MRI). CT scan of the abdomen shows a thrombus as a densely packed vein. CT scan is also additionally beneficial since it shows other pathology that might be present such as a cancerous tumor. Another diagnostic tool for portal vein thrombosis is angiography. Angiography is not as frequently considered as a CT or MRI; it is a more invasive evaluation mostly used when planning shunt surgery.<xref ref-type="bibr" rid="article-36712.r7">[7]</xref></p>
        <p>Doppler ultrasound is the best initial diagnostic test in cases&#x000a0;with a suspicion of splenic vein thrombosis when considering all these facts. A normal splenic vein Doppler makes diagnosing splenic vein thrombosis highly improbable. In mesenteric venous thrombosis, study results have shown that a CT scan of the abdomen has 90% accuracy. In cases where a CT scan is nondiagnostic, it is suggested to do CT angiography. Magnetic resonance (MR) venography is the most reliable imaging for mesenteric venous thrombosis. However, most cases can be seen on a CT scan without MR venography.<xref ref-type="bibr" rid="article-36712.r9">[9]</xref>&#x000a0;Doppler ultrasound diagnoses hepatic venous thrombosis, and a CT scan of the abdomen or MRI confirms it. Doppler shows hyperechoic material in the hepatic vein and other findings such as hepatomegaly, ascites, or hepatic lobe atrophy.</p>
        <p>
<bold>Laboratory</bold>
</p>
        <p>Checking for coagulation defects in anyone with thrombosis and, most specifically, patients with portal vein thrombosis without cirrhosis is essential.</p>
        <p>
<bold>Endoscopy</bold>
</p>
        <p>An upper endoscopy is needed in cases of hematemesis or upper gastrointestinal bleeding, as an endoscopy checks and confirms variceal bleeding. Patients with portal vein thrombosis and cirrhosis&#x000a0;are monitored for varices (esophageal or gastric) by endoscopy; this fact holds accurate about patients with splenic vein thrombosis.</p>
      </sec>
      <sec id="article-36712.s7" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>There are multiple steps when treating splanchnic venous thrombosis, all of which reduce mortality and morbidity. Treating the underlying cause, the thrombosis itself, and the complications that it causes, such as variceal bleeding is important. There is no consensus when treating splanchnic venous thrombosis. Results from small uncontrolled studies have shown that systemic anticoagulation improved survival and lowered recurrence.<xref ref-type="bibr" rid="article-36712.r11">[11]</xref>&#x000a0;American College of Chest Physicians recommends treating symptomatic patients with anticoagulation; patients who are asymptomatic should not be treated.<xref ref-type="bibr" rid="article-36712.r12">[12]</xref></p>
        <p>By&#x000a0;1 estimate, about 25% of splanchnic vein thrombosis cases present with gastrointestinal bleeding at diagnosis.<xref ref-type="bibr" rid="article-36712.r13">[13]</xref>&#x000a0;These are usually from&#x000a0;esophageal varices. The decision to treat with anticoagulation, therefore, should be individualized. Potential risks, such as bleeding, should be weighed against the therapy benefits. Active bleeding is a contraindication for anticoagulation, but a history of previous bleeding is not.<xref ref-type="bibr" rid="article-36712.r14">[14]</xref></p>
        <p>Study results have shown that patients with cirrhosis with portal vein thrombosis benefits from anticoagulation therapy. They have&#x000a0;a lower rate of variceal bleeding when treated. Isolated portal vein thrombosis without cirrhosis is not as clear of a scenario. However, study results have not shown an increase&#x000a0;in episodes of&#x000a0;bleeding after anticoagulation therapy.<xref ref-type="bibr" rid="article-36712.r7">[7]</xref></p>
        <p>Low molecular weight heparin (LMWH) is the drug of choice for anticoagulation. Splanchnic vein thrombosis cases have an increased risk of gastrointestinal bleeding, and therefore, LMWH (with a shorter half-life than warfarin) is the preferred medication. Additionally, by&#x000a0;1 estimate, 22% to 27% of patients with splanchnic vein thrombosis have underlying solid malignancy. LMWH is traditionally used more frequently and effectively than warfarin in cancer cases.<xref ref-type="bibr" rid="article-36712.r12">[12]</xref> The duration of anticoagulation therapy depends on the underlying cause. All patients with splanchnic vein thrombosis should probably be anticoagulated for at least 3 months. A reason for stopping anticoagulation is a high risk of bleeding. Hypercoagulable states require more extended periods of treatment.<xref ref-type="bibr" rid="article-36712.r14">[14]</xref></p>
        <p>There are&#x000a0;2 studies providing results and several articles on using direct oral anticoagulant medications (dabigatran&#x000a0;etexilate, rivaroxaban, apixaban, and edoxaban) in splanchnic vein thrombosis. Overall, there was an increased risk of gastrointestinal bleeding using rivaroxaban as compared to LMWH.<xref ref-type="bibr" rid="article-36712.r15">[15]</xref><xref ref-type="bibr" rid="article-36712.r16">[16]</xref>&#x000a0;Furthermore,&#x000a0;the use of direct oral anticoagulants is contraindicated in patients with an underlying liver impairment since their metabolism is through the cytochrome P (CYP)3A4 system.<xref ref-type="bibr" rid="article-36712.r17">[17]</xref>&#x000a0;</p>
        <p>In cases of symptomatic splenic vein thrombosis, splenectomy is the best treatment. The role of splenectomy is unclear in patients who are asymptomatic. Such patients have a low risk of bleeding and can be observed and treated with splenectomy if they become symptomatic.<xref ref-type="bibr" rid="article-36712.r8">[8]</xref>&#x000a0;Patients with cirrhosis and portal vein thrombosis need screening for esophageal varices, even in the absence of bleeding; this is done by upper endoscopy to prevent future variceal bleeding. If esophageal varices were found during screening, the patient should be prophylactically treated with nonselective beta-blocker drugs.<xref ref-type="bibr" rid="article-36712.r7">[7]</xref></p>
      </sec>
      <sec id="article-36712.s8" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Differential diagnosis to consider and rule out regarding splanchnic venous thrombosis include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Arsenic toxicity</p>
          </list-item>
          <list-item>
            <p>Budd-Chiari syndrome</p>
          </list-item>
          <list-item>
            <p>Cirrhosis</p>
          </list-item>
          <list-item>
            <p>Congenital hepatic fibrosis</p>
          </list-item>
          <list-item>
            <p>Granulomatous hepatitis</p>
          </list-item>
          <list-item>
            <p>Hepatoportal sclerosis</p>
          </list-item>
          <list-item>
            <p>Primary biliary cirrhosis</p>
          </list-item>
          <list-item>
            <p>Sarcoidosis</p>
          </list-item>
          <list-item>
            <p>Schistosomiasis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-36712.s9" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Morbidity and mortality of splanchnic vein thrombosis have improved over the years with treatment. This is mainly due to earlier diagnosis and treatment of the condition. In a study that followed 136 patients with chronic portal vein thrombosis for 5 years, results showed fewer than 5% of patients died of complications of thrombosis, such as gastrointestinal bleeding. However, the mortality rate is higher in patients who have mesenteric vein thrombosis in addition to portal vein thrombosis.<xref ref-type="bibr" rid="article-36712.r11">[11]</xref>&#x000a0;Results from a study of 3700 patients with mesenteric vein thrombosis showed the mortality rate was 44% compared to a 66% mortality rate in arterial mesenteric thrombosis.<xref ref-type="bibr" rid="article-36712.r18">[18]</xref> However, the mortality rate is higher in patients with intestinal infarction.<xref ref-type="bibr" rid="article-36712.r19">[19]</xref></p>
      </sec>
      <sec id="article-36712.s10" sec-type="Complications">
        <title>Complications</title>
        <p>Left-sided portal hypertension results from complete obstruction of the splenic vein; this does not occur in all cases due to anatomic variants. Many patients are asymptomatic, and significant splenomegaly may be detected on imaging. The patient may present with typical signs of portal hypertension, including gastroesophageal varices, ascites, and splenomegaly, which cannot be attributed to hepatic disease. Some of the complications of splanchnic venous thrombosis include gastrointestinal bleeding, esophageal or gastric varices, intestinal ischemia, anemia, thrombocytopenia, and infection.</p>
      </sec>
      <sec id="article-36712.s11" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>This is a rare medical condition, therefore, patient education is beneficial.&#x000a0;Splanchnic venous thrombosis patient education emphasizes recognizing abdominal pain symptoms and seeking prompt medical attention. Deterrence strategies include educating patients on risk factors, promoting lifestyle modifications, and ensuring awareness of early signs, fostering a proactive approach to reduce the likelihood and severity of splanchnic venous thrombosis.</p>
      </sec>
      <sec id="article-36712.s12" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>A collaborative effort between the primary care clinician, gastroenterologist, radiologist, surgeon, and hematologist is of the essence in recognizing and efficiently dealing with this rare entity. A lack of knowledge and understanding of the disease and its predisposing factors and a lack of an interprofessional approach cause complications.</p>
      </sec>
      <sec id="article-36712.s13">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=36712&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=36712">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/heart-health/splanchnic-venous-thrombosis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=36712">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/36712/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=36712">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-36712.s14">
        <title>References</title>
        <ref id="article-36712.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ageno</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Riva</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Schulman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Beyer-Westendorf</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bang</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Senzolo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grandone</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pasca</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Di Minno</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Duce</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Malato</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Santoro</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Poli</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Verhamme</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Martinelli</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kamphuisen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Oh</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>D'Amico</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Becattini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>De Stefano</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Vidili</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vaccarino</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nardo</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Di Nisio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dentali</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Long-term Clinical Outcomes of Splanchnic Vein Thrombosis: Results of an International Registry.</article-title>
            <source>JAMA Intern Med</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>175</volume>
            <issue>9</issue>
            <fpage>1474</fpage>
            <page-range>1474-80</page-range>
            <pub-id pub-id-type="pmid">26168152</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36712.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Acosta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Alhadad</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Svensson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ekberg</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology, risk and prognostic factors in mesenteric venous thrombosis.</article-title>
            <source>Br J Surg</source>
            <year>2008</year>
            <month>Oct</month>
            <volume>95</volume>
            <issue>10</issue>
            <fpage>1245</fpage>
            <page-range>1245-51</page-range>
            <pub-id pub-id-type="pmid">18720461</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36712.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fimognari</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Violi</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Portal vein thrombosis in liver cirrhosis.</article-title>
            <source>Intern Emerg Med</source>
            <year>2008</year>
            <month>Sep</month>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>213</fpage>
            <page-range>213-8</page-range>
            <pub-id pub-id-type="pmid">18274708</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36712.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agarwal</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Raj Kumar</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Significance of splenic vein thrombosis in chronic pancreatitis.</article-title>
            <source>Am J Surg</source>
            <year>2008</year>
            <month>Aug</month>
            <volume>196</volume>
            <issue>2</issue>
            <fpage>149</fpage>
            <page-range>149-54</page-range>
            <pub-id pub-id-type="pmid">18585674</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36712.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abu-Daff</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Abu-Daff</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Al-Shahed</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Mesenteric venous thrombosis and factors associated with mortality: a statistical analysis with five-year follow-up.</article-title>
            <source>J Gastrointest Surg</source>
            <year>2009</year>
            <month>Jul</month>
            <volume>13</volume>
            <issue>7</issue>
            <fpage>1245</fpage>
            <page-range>1245-50</page-range>
            <pub-id pub-id-type="pmid">19296183</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36712.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Darwish Murad</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Valla</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>de Groen</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Zeitoun</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hopmans</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Haagsma</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>van Hoek</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Rosendaal</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Janssen</surname>
                <given-names>HL</given-names>
              </name>
            </person-group>
            <article-title>Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome.</article-title>
            <source>Hepatology</source>
            <year>2004</year>
            <month>Feb</month>
            <volume>39</volume>
            <issue>2</issue>
            <fpage>500</fpage>
            <page-range>500-8</page-range>
            <pub-id pub-id-type="pmid">14768004</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36712.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sogaard</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Astrup</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Vilstrup</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gronbaek</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Portal vein thrombosis; risk factors, clinical presentation and treatment.</article-title>
            <source>BMC Gastroenterol</source>
            <year>2007</year>
            <month>Aug</month>
            <day>15</day>
            <volume>7</volume>
            <fpage>34</fpage>
            <pub-id pub-id-type="pmid">17697371</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36712.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sakorafas</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Sarr</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Farley</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Farnell</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <article-title>The significance of sinistral portal hypertension complicating chronic pancreatitis.</article-title>
            <source>Am J Surg</source>
            <year>2000</year>
            <month>Feb</month>
            <volume>179</volume>
            <issue>2</issue>
            <fpage>129</fpage>
            <page-range>129-33</page-range>
            <pub-id pub-id-type="pmid">10773149</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36712.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harward</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bergan</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Rizzo</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Mesenteric venous thrombosis.</article-title>
            <source>J Vasc Surg</source>
            <year>1989</year>
            <month>Feb</month>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>328</fpage>
            <page-range>328-33</page-range>
            <pub-id pub-id-type="pmid">2918628</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36712.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Plessier</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Valla</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Budd-Chiari syndrome.</article-title>
            <source>Semin Liver Dis</source>
            <year>2008</year>
            <month>Aug</month>
            <volume>28</volume>
            <issue>3</issue>
            <fpage>259</fpage>
            <page-range>259-69</page-range>
            <pub-id pub-id-type="pmid">18814079</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36712.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Condat</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pessione</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hillaire</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Denninger</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Guillin</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Poliquin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hadengue</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Erlinger</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Valla</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy.</article-title>
            <source>Gastroenterology</source>
            <year>2001</year>
            <month>Feb</month>
            <volume>120</volume>
            <issue>2</issue>
            <fpage>490</fpage>
            <page-range>490-7</page-range>
            <pub-id pub-id-type="pmid">11159889</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36712.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kearon</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Akl</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Comerota</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Prandoni</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bounameaux</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Goldhaber</surname>
                <given-names>SZ</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Wells</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Gould</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Dentali</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Crowther</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kahn</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</article-title>
            <source>Chest</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>141</volume>
            <issue>2 Suppl</issue>
            <fpage>e419S</fpage>
            <page-range>e419S-e496S</page-range>
            <pub-id pub-id-type="pmid">22315268</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36712.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Senzolo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cholongitas</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Patch</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Burroughs</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Update on the classification, assessment of prognosis and therapy of Budd-Chiari syndrome.</article-title>
            <source>Nat Clin Pract Gastroenterol Hepatol</source>
            <year>2005</year>
            <month>Apr</month>
            <volume>2</volume>
            <issue>4</issue>
            <fpage>182</fpage>
            <page-range>182-90</page-range>
            <pub-id pub-id-type="pmid">16265183</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36712.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ageno</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Beyer-Westendorf</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Lazo-Langner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McBane</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Paciaroni</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Guidance for the management of venous thrombosis in unusual sites.</article-title>
            <source>J Thromb Thrombolysis</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>41</volume>
            <issue>1</issue>
            <fpage>129</fpage>
            <page-range>129-43</page-range>
            <pub-id pub-id-type="pmid">26780742</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36712.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Gottardi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Trebicka</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Klinger</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Plessier</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Seijo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Terziroli</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Magenta</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Semela</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Buscarini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Langlet</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>G&#x000f6;rtzen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Puente</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>M&#x000fc;llhaupt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Navascu&#x000e8;s</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nery</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Deltenre</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Turon</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Engelmann</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Arya</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Caca</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Peck-Radosavljevic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Leebeek</surname>
                <given-names>FWG</given-names>
              </name>
              <name>
                <surname>Valla</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Garcia-Pagan</surname>
                <given-names>JC</given-names>
              </name>
              <collab>VALDIG Investigators</collab>
            </person-group>
            <article-title>Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis.</article-title>
            <source>Liver Int</source>
            <year>2017</year>
            <month>May</month>
            <volume>37</volume>
            <issue>5</issue>
            <fpage>694</fpage>
            <page-range>694-699</page-range>
            <pub-id pub-id-type="pmid">27778440</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36712.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Janczak</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Mimier</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>McBane</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Kamath</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Simmons</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Bott-Kitslaar</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Lenz</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Vargas</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Hodge</surname>
                <given-names>DO</given-names>
              </name>
              <name>
                <surname>Wysokinski</surname>
                <given-names>WE</given-names>
              </name>
            </person-group>
            <article-title>Rivaroxaban and Apixaban for Initial Treatment of Acute Venous Thromboembolism of Atypical Location.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>93</volume>
            <issue>1</issue>
            <fpage>40</fpage>
            <page-range>40-47</page-range>
            <pub-id pub-id-type="pmid">29217335</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36712.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ageno</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Gallus</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Wittkowsky</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Crowther</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hylek</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Palareti</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</article-title>
            <source>Chest</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>141</volume>
            <issue>2 Suppl</issue>
            <fpage>e44S</fpage>
            <page-range>e44S-e88S</page-range>
            <pub-id pub-id-type="pmid">22315269</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36712.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schoots</surname>
                <given-names>IG</given-names>
              </name>
              <name>
                <surname>Koffeman</surname>
                <given-names>GI</given-names>
              </name>
              <name>
                <surname>Legemate</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Levi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van Gulik</surname>
                <given-names>TM</given-names>
              </name>
            </person-group>
            <article-title>Systematic review of survival after acute mesenteric ischaemia according to disease aetiology.</article-title>
            <source>Br J Surg</source>
            <year>2004</year>
            <month>Jan</month>
            <volume>91</volume>
            <issue>1</issue>
            <fpage>17</fpage>
            <page-range>17-27</page-range>
            <pub-id pub-id-type="pmid">14716789</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36712.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Acosta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Alhadad</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ekberg</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Findings in multi-detector row CT with portal phase enhancement in patients with mesenteric venous thrombosis.</article-title>
            <source>Emerg Radiol</source>
            <year>2009</year>
            <month>Nov</month>
            <volume>16</volume>
            <issue>6</issue>
            <fpage>477</fpage>
            <page-range>477-82</page-range>
            <pub-id pub-id-type="pmid">19294438</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
